Ischemic Stroke Drug Pipeline Analysis Report 2025
Description
An ischemic stroke happens when blood supply to the brain is blocked, usually by a blood clot or fatty plaque accumulation in the arteries. Due to this obstruction, there is less oxygen and nutrition available, which damages or kills brain cells. About 87% of all strokes are ischemic strokes, which fall into two primary categories, namely, embolic strokes (clots originate from other areas of the body) and thrombotic strokes (clots form in the arteries of the brain). To reduce brain damage and enhance recovery, prompt therapy is essential. The rising prevalence of the condition is anticipated to positively impact the pipeline landscape for ischemic stroke drugs.
Report Coverage
The Ischemic Stroke Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ischemic stroke therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ischemic stroke. The ischemic stroke report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The ischemic stroke pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with ischemic stroke treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ischemic stroke.
Ischemic Stroke Drug Pipeline Outlook
The pathophysiology of an ischemic stroke starts when blood supply to the brain is blocked, frequently because of thromboembolic incidents. As a result, cellular hypoxia and adenosine triphosphate (ATP) depletion occur, upsetting ion homeostasis and depolarizing neurons. Cytotoxic edema is the outcome of too many calcium and sodium ions entering cells. While the penumbra (the area of brain tissue surrounding the ischemic core) contains tissue that can be salvaged, the ischemic core, where blood supply is drastically restricted, undergoes fast cell death. Damage is made worse by inflammatory reactions, which can result in neuronal death and other long-term impairments if left untreated.
The best treatment for acute ischemic stroke is a small molecule, specifically alteplase (also known as recombinant tissue plasminogen activator, or rt-PA). It is a fibrinolytic drug that is administered intravenously to break up clots and replenish blood supply to the brain. Alteplase is still the sole FDA-approved medication for acute ischemic stroke within a certain time frame, even though other medications like heparins (antithrombotic) and anti-inflammatory drugs may be utilized. Although it is currently at the preclinical stage, research is being done on novel compounds like LK-2, which protects neurons by targeting glutamate activity. Further, the rising focus on the development of ischemic stroke emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Ischemic Stroke Epidemiology
Globally, ischemic stroke affects approximately 77.19 million individuals, with a notable increase in cases over recent years. In 2020, there were around 7.86 million new cases of ischemic stroke, contributing to significant mortality and disability. The incidence is higher in low- and middle-income countries, where healthcare access is often limited. Women account for about 56% of ischemic stroke cases. Projections indicate that the number of cases may rise to 9.62 million by 2030, highlighting the growing burden of this condition worldwide.
Ischemic Stroke – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of ischemic stroke drug candidates based on several segmentations including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials, with a substantial number of ischemic stroke drugs undergoing clinical development.
Ischemic Stroke – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under ischemic stroke pipeline analysis include recombinant fusion proteins, small molecules, biologics, peptides, polymers, and monoclonal antibodies, among others. The ischemic stroke report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ischemic stroke.
Ischemic Stroke Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the ischemic stroke drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ischemic stroke therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ischemic stroke clinical trials:
Major drugs currently in the drug pipeline are as follows:
Drug: Evolocumab
Amgen is developing Evolocumab, a PCSK9 inhibitor, for ischemic stroke prevention. In the Phase 3 of FOURIER trial, adding Evolocumab to statin therapy reduced ischemic stroke risk by 25% compared to a placebo. Building on these findings, the ongoing Phase 4 EVOLVE-MI trial is evaluating the impact of early Evolocumab administration in reducing cardiovascular events, including ischemic stroke, in patients hospitalized for acute myocardial infarction.
Drug: Lerodalcibep
Lerodalcibep, developed by LIB Therapeutics LLC, is a novel, subcutaneous PCSK9 inhibitor designed to significantly reduce low-density lipoprotein cholesterol (LDL-C). While primarily targeting hypercholesterolemia and cardiovascular diseases, current clinical trials do not indicate its development for ischemic stroke treatment. Its potent LDL-C-lowering effects may indirectly benefit stroke prevention by addressing atherosclerotic risk factors.
Reasons To Buy This Report
The Ischemic Stroke Drug Report provides a strategic overview of the latest and future landscape of treatments for ischemic stroke. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the ischemic stroke pipeline insights.
Key Questions Answered in the Ischemic Stroke – Pipeline Insight Report
Ischemic Stroke Market
Global Clinical Trials Market
Report Coverage
The Ischemic Stroke Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ischemic stroke therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ischemic stroke. The ischemic stroke report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The ischemic stroke pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with ischemic stroke treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ischemic stroke.
Ischemic Stroke Drug Pipeline Outlook
The pathophysiology of an ischemic stroke starts when blood supply to the brain is blocked, frequently because of thromboembolic incidents. As a result, cellular hypoxia and adenosine triphosphate (ATP) depletion occur, upsetting ion homeostasis and depolarizing neurons. Cytotoxic edema is the outcome of too many calcium and sodium ions entering cells. While the penumbra (the area of brain tissue surrounding the ischemic core) contains tissue that can be salvaged, the ischemic core, where blood supply is drastically restricted, undergoes fast cell death. Damage is made worse by inflammatory reactions, which can result in neuronal death and other long-term impairments if left untreated.
The best treatment for acute ischemic stroke is a small molecule, specifically alteplase (also known as recombinant tissue plasminogen activator, or rt-PA). It is a fibrinolytic drug that is administered intravenously to break up clots and replenish blood supply to the brain. Alteplase is still the sole FDA-approved medication for acute ischemic stroke within a certain time frame, even though other medications like heparins (antithrombotic) and anti-inflammatory drugs may be utilized. Although it is currently at the preclinical stage, research is being done on novel compounds like LK-2, which protects neurons by targeting glutamate activity. Further, the rising focus on the development of ischemic stroke emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Ischemic Stroke Epidemiology
Globally, ischemic stroke affects approximately 77.19 million individuals, with a notable increase in cases over recent years. In 2020, there were around 7.86 million new cases of ischemic stroke, contributing to significant mortality and disability. The incidence is higher in low- and middle-income countries, where healthcare access is often limited. Women account for about 56% of ischemic stroke cases. Projections indicate that the number of cases may rise to 9.62 million by 2030, highlighting the growing burden of this condition worldwide.
Ischemic Stroke – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of ischemic stroke drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Recombinant Fusion Proteins
- Small Molecule
- Peptide
- Polymer
- Monoclonal Antibody
- Gene Therapy
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials, with a substantial number of ischemic stroke drugs undergoing clinical development.
Ischemic Stroke – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under ischemic stroke pipeline analysis include recombinant fusion proteins, small molecules, biologics, peptides, polymers, and monoclonal antibodies, among others. The ischemic stroke report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ischemic stroke.
Ischemic Stroke Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the ischemic stroke drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ischemic stroke therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ischemic stroke clinical trials:
- Amgen
- LIB Therapeutics LLC
- NC Medial Research Inc
- Allife Medical Science and Technology Co., Ltd.
- Shanghai Hutchison Pharmaceuticals Limited
Major drugs currently in the drug pipeline are as follows:
Drug: Evolocumab
Amgen is developing Evolocumab, a PCSK9 inhibitor, for ischemic stroke prevention. In the Phase 3 of FOURIER trial, adding Evolocumab to statin therapy reduced ischemic stroke risk by 25% compared to a placebo. Building on these findings, the ongoing Phase 4 EVOLVE-MI trial is evaluating the impact of early Evolocumab administration in reducing cardiovascular events, including ischemic stroke, in patients hospitalized for acute myocardial infarction.
Drug: Lerodalcibep
Lerodalcibep, developed by LIB Therapeutics LLC, is a novel, subcutaneous PCSK9 inhibitor designed to significantly reduce low-density lipoprotein cholesterol (LDL-C). While primarily targeting hypercholesterolemia and cardiovascular diseases, current clinical trials do not indicate its development for ischemic stroke treatment. Its potent LDL-C-lowering effects may indirectly benefit stroke prevention by addressing atherosclerotic risk factors.
Reasons To Buy This Report
The Ischemic Stroke Drug Report provides a strategic overview of the latest and future landscape of treatments for ischemic stroke. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the ischemic stroke pipeline insights.
Key Questions Answered in the Ischemic Stroke – Pipeline Insight Report
- What is the current landscape of ischemic stroke pipeline drugs?
- Which companies/institutions are developing ischemic stroke emerging drugs?
- How many phase II drugs are currently present in ischemic stroke pipeline drugs?
- Which company is leading the ischemic stroke pipeline development activities?
- What is the current ischemic stroke therapeutic assessment?
- What are the opportunities and challenges present in the ischemic stroke drug pipeline landscape?
- What is the efficacy and safety profile of ischemic stroke pipeline drugs?
- Which companies/institutions are involved in ischemic stroke collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in ischemic stroke ?
Ischemic Stroke Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Ischemic Stroke
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Ischemic Stroke
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Ischemic Stroke
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Ischemic Stroke: Epidemiology Snapshot
- 5.1 Ischemic Stroke Incidence by Key Markets
- 5.2 Ischemic Stroke – Patients Seeking Treatment in Key Markets
- 6 Ischemic Stroke: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Ischemic Stroke: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Ischemic Stroke, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Ischemic Stroke Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Ischemic Stroke Drug Pipeline - Mid-Stage Products (Phase III & IV) (Top Drugs)
- 10.1 Comparative Analysis for Mid-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Evolocumab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Lerodalcibep
- 10.2.3 Other Drugs
- 11 Ischemic Stroke Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: NCS-01
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: SHPL-49
- 11.2.3 Other Drugs
- 12 Ischemic Stroke Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: iEPCs
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Ischemic Stroke, Key Drug Pipeline Companies
- 13.1 Amgen
- 13.1.1 Company Snapshot
- 13.1.2 Pipeline Product Portfolio
- 13.1.3 Financial Analysis
- 13.1.4 Recent News and Developments
- 13.2 LIB Therapeutics LLC
- 13.2.1 Company Snapshot
- 13.2.2 Pipeline Product Portfolio
- 13.2.3 Financial Analysis
- 13.2.4 Recent News and Developments
- 13.3 NC Medial Research Inc.
- 13.3.1 Company Snapshot
- 13.3.2 Pipeline Product Portfolio
- 13.3.3 Financial Analysis
- 13.3.4 Recent News and Developments
- 13.4 Allife Medical Science and Technology Co., Ltd.
- 13.4.1 Company Snapshot
- 13.4.2 Pipeline Product Portfolio
- 13.4.3 Financial Analysis
- 13.4.4 Recent News and Developments
- 13.5 Shanghai Hutchison Pharmaceuticals Limited
- 13.5.1 Company Snapshot
- 13.5.2 Pipeline Product Portfolio
- 13.5.3 Financial Analysis
- 13.5.4 Recent News and Developments
- 14 Regulatory Framework for Drug Approval, By Region
- 15 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
